Rapid Hit and Hit-to-Lead Generation in Early Drug Discovery

webinar

Wed, 21 Sep 2022, 14:00 CEST (Berlin)

Dr. Debanu Das, XPose Therapeutics, San Francisco, United States of America

Rapid Hit and Hit-to-Lead Generation in Early Drug Discovery

Join us for this webinar! XPose Therapeutics discovers and develops first-in-class target-specific therapeutics, including small molecule inhibitors and targeted protein degraders based on fragment- and structure-based drug discovery. Their approach, “SAR by X-ray Poses Quickly” (“SaXPy”), is founded on a novel technology with two parts: High-throughput X-ray screening of fragment libraries as a primary screen for hit generation, combined with the elucidation of fragment-bound crystal structures. This speeds up fast hit-to-lead development by analog scoping, scaffold hopping, and fragment growth, thus leading to several-fold reduction in early drug discovery efforts.
Debanu will discuss the discovery and complex structure elucidation of novel agents against DNA Damage Response (DDR) targets. These include APE1 and POL η — the first crystal structures of two DDR proteins bound to small molecule ligands. Further, he will present work on FEN1 inhibitors with a KD of 170 nM and discuss how new therapeutics development is facilitated by applying their approach to numerous proteins. Special focus shall be given on novel targets that have rich biology and scientific validation but lack clinical inhibitors (“undruggables”). Debanu will also present how the group’s APE1 inhibitors can be translated for related DDR endonucleases, APE2 and LINE1. Exciting challenges to listen to!

Current news

category
Challenge
Winner of Fall 2021 Scientific Challenge: Aaron Kuriakose Prakash with Covalent Tuberculosis Drugs
September 20, 2022 12:56 CEST
We are excited to announce the winner of the Fall 2021 Scientific Challenge: Aaron Kuriakose Prakash from the Madras Christian College (Chennai, India)! In the past twelve months he used the covalent docking feature of SeeSAR to screen for potential drug candidates to treat tuberculosis infections. He got the best...
Read on
category
Software
Introducing eXplore — a New Trillion-Sized Chemical Space by eMolecules
September 12, 2022 13:06 CEST
eXplore – the largest commercial Chemical Space featuring over 2.8 trillion tangible compounds is now available. Created jointly with eMolecules, the Chemical Space was designed to provide users with accessible compounds to match their needs during a drug discovery project. eXplore has been created with a selection of eMolecules’s building...
Read on
category
Events
Recap Drugathon 2022
July 13, 2022 13:10 CEST
The first BioSolveIT Drugathon has concluded and the feedback is overwhelming. Over 400 people from around the globe have registered to this unique drug discovery event where research from around the globe collaborate on a single target structure to design novel compounds. The group of Prof. Anna Hirsch volunteered to...
Read on